My Personal Therapeutics and Pentavere receive EUREKA Artificial Intelligence/Quantum Therapeutics Funding

My Personal Therapeutics, a London-based medtech/digital therapeutics company and Pentavere Research Group, a Canadian-based Artificial Intelligence and data insight company announced their successful EUREKA Collaborative R&D: AI and Quantum Technologies Competition award for project titled “Utilisation of AI to develop Personalised Treatment Plans for cancer”. Funding totalling £792,000 is co-funded by the UK’s innovation agency, Innovate UK, and Canada’s National Research Council’s Industrial Research Assistant Program, as part of their Collaborate R&D programme. These funds will be used by Pentavere Research Group and My Personal Therapeutics to access Genomics England’s whole genome sequencing lung cancer data set and selectively generate drosophila avatars for high-throughput drug screening. The resulting tumour genomic profile and corresponding drug treatment recommendation data will feed into our AI Personal Discovery Process predictive model. Potentially, some of the funding can support personalised treatment recommendations for lung cancer patients in the UK.

“This Eureka award will partly fund this ground-breaking collaboration between My Personal Therapeutics, Pentavere and Genomics England towards the development of our rapid personalised cancer therapeutics offering – AI PDP” shared My Personal Therapeutics’ CEO Laura Towart.

About EUREKA
EUREKA is a publicly-funded, intergovernmental network, involving over 40 countries. EUREKA’s aim is to enhance European competitiveness by fostering innovation-driven entrepreneurship in Europe, between small and large industry, research institutes and universities. By doing this, EUREKA concentrates the existing potential of experts, of knowledge, research facilities and financial resources in a more efficient way. EUREKA is constantly proving its value through a wealth of success stories – innovative products, processes and services that have been launched onto the market over the last 30 years, creating additional turnover and jobs for European companies, small and large – and by supporting the internationalization of businesses with innovative ideas.

EUREKA is a leading open platform for international cooperation in innovation. It remains to this day the only initiative of its kind committed to the ‘bottom-up’ principle – ensuring that any R&D project with a good business plan receives the support it deserves, independent of its technological nature, or the type of organisations involved.

Nicole Cox:
Media and Client Services Executive | Life Science Newswire
ncox@lifesciencenewswire.com